肿瘤来源的溶血磷脂酸削弱卵巢癌中保护性I型干扰素应答
本文报道溶血磷脂酸(LPA)在卵巢癌中作为I型干扰素应答的负调控因子发挥作用。在卵巢癌细胞中敲除LPA生成酶自分泌运动因子(ATX)可重编程肿瘤免疫微环境、延长宿主生存并改善依赖I型干扰素保护性应答的疗效。树突状细胞感知LPA后触发PGE2生物合成,通过自分泌EP4结合抑制I型干扰素信号;LPA调控的免疫来源基因特征与卵巢癌患者对PARP抑制联合PD-1阻断的不良应答相关。
要点
- LPA在卵巢癌中作为I型干扰素应答的负调控因子发挥作用。
- 敲除卵巢癌细胞ATX可重编程免疫微环境、延长宿主生存并改善I型干扰素依赖疗效。
- 树突状细胞感知LPA触发PGE2合成,经自分泌EP4抑制I型干扰素信号。
核心结论
- LPA在卵巢癌中作为I型干扰素应答的负调控因子发挥作用。
- 在肿瘤中控制LPA的产生或感知可能有助于改善依赖I型干扰素强诱导的癌症免疫治疗。
研究设计与样本
- 本文为实验研究,在卵巢癌细胞中敲除LPA生成酶自分泌运动因子(ATX)并分析肿瘤免疫微环境与宿主生存。
主要发现
- 卵巢癌细胞中敲除ATX可重编程肿瘤免疫微环境、延长宿主生存并改善依赖I型干扰素保护性应答的疗效。
- 树突状细胞感知LPA触发PGE2生物合成,通过自分泌EP4结合抑制I型干扰素信号。
- 鉴定出LPA调控的免疫来源基因特征,与卵巢癌患者对PARP抑制联合PD-1阻断的不良应答相关。
临床怎么用
- 作者认为控制肿瘤中LPA的产生或感知可能有助于改善依赖I型干扰素强诱导的癌症免疫治疗。
- 作者认为理解LPA诱导的免疫调控程序可能带来预测癌症患者免疫治疗耐药的新生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Lysophosphatidic acid (LPA) is a bioactive lipid enriched in the tumor microenvironment of immunosuppressive malignancies such as ovarian cancer. Although LPA enhances the tumorigenic attributes of cancer cells, the immunomodulatory activity of this phospholipid messenger remains largely unexplored. Here, we report that LPA operates as a negative regulator of type I interferon (IFN) responses in ovarian cancer. Ablation of the LPA-generating enzyme autotaxin (ATX) in ovarian cancer cells reprogrammed the tumor immune microenvironment, extended host survival, and improved the effects of therapies that elicit protective responses driven by type I IFN. Mechanistically, LPA sensing by dendritic cells triggered PGE2 biosynthesis that suppressed type I IFN signaling via autocrine EP4 engagement. Moreover, we identified an LPA-controlled, immune-derived gene signature associated with poor responses to combined PARP inhibition and PD-1 blockade in patients with ovarian cancer. Controlling LPA production or sensing in tumors may therefore be useful to improve cancer immunotherapies that rely on robust induction of type I IFN. SIGNIFICANCE: This study uncovers that ATX-LPA is a central immunosuppressive pathway in the ovarian tumor microenvironment. Ablating this axis sensitizes ovarian cancer hosts to various immunotherapies by unleashing protective type I IFN responses. Understanding the immunoregulatory programs induced by LPA could lead to new biomarkers predicting resistance to immunotherapy in patients with cancer. See related commentary by Conejo-Garcia and Curiel, p. 1841. This article is highlighted in the In This Issue feature, p. 1825.
引用
- Chae CS, Sandoval TA, Hwang SM, et al. Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer. Cancer Discov. 2022. PMID: 35552618. doi:10.1158/2159-8290.CD-21-1181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。